Drug Trial Radar · NCT05882045
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Last checked: Nov 20, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,946
Actual
Start
May 30, 2023
Primary completion
Apr 16, 2026
Study completion May 14, 2026
Sponsor
- Lead sponsor
- Eli Lilly and CompanyEli Lilly (LLY)
- Sponsor type
- Industry
- First posted
- May 31, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Conditions
- Obesity
- Cardiovascular Diseases
Interventions
RetatrutideDrug
Administered SC
PlaceboDrug
Administered SC
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Body WeightTime frame: Baseline, Week 80
Locations
169 sites in 10 countries. Site status is shown where the registry gives one.
Central Phoenix Medical Clinic
Phoenix, Arizona
Valley Clinical Trials, Inc.
Covina, California
Neuro-Pain Medical Center
Fresno, California
Valley Research
Fresno, California
Collaborative Neuroscience Research, LLC
Los Alamitos, California
Velocity Clinical Research, Westlake
Los Angeles, California
Valley Clinical Trials, Inc.
Northridge, California
Velocity Clinical Research, Panorama City
Van Nuys, California
Chase Medical Research, LLC
Waterbury, Connecticut
Indago Research & Health Center, Inc
Hialeah, Florida
Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
Jacksonville, Florida
Clinical Neuroscience Solutions, Inc.
Orlando, Florida
Charter Research - Winter Park
Orlando, Florida
Progressive Medical Research
Port Orange, Florida
Pacific Diabetes & Endocrine Center
Honolulu, Hawaii
Elite Clinical Trials
Blackfoot, Idaho
Humphreys Diabetes Center
Boise, Idaho
Northwestern University
Chicago, Illinois
Great Lakes Clinical Trials - Gurnee
Gurnee, Illinois
Central Illinois Diabetes and Clinical Research a Division of Prairie Education and Research Cooperative
Springfield, Illinois
Brengle Family Medicine
Indianapolis, Indiana
Iowa Diabetes and Endocrinology Research Center
West Des Moines, Iowa
Cotton O'Neil Diabetes & Endocrinology
Topeka, Kansas
MedVadis Research Corporation
Waltham, Massachusetts
StudyMetrix Research
City of Saint Peters, Missouri
Las Vegas Medical Research
Las Vegas, Nevada
Palm Research Center Tenaya
Las Vegas, Nevada
IMA Clinical Research Warren
Warren Township, New Jersey
Weill Cornell Medical College
New York, New York
Rochester Clinical Research, LLC
Rochester, New York
Carteret Medical Group
Morehead City, North Carolina
Cleveland Clinic
Cleveland, Ohio
Altoona Center For Clinical Research
Duncansville, Pennsylvania
UPMC Montefiore University Hospital
Pittsburgh, Pennsylvania
Tribe Clinical Research, LLC
Greenville, South Carolina
Trial Management Associates
Myrtle Beach, South Carolina
Tribe Clinical Research - Spartanburg
Spartanburg, South Carolina
Texas Diabetes & Endocrinology, P.A.
Austin, Texas
Pinnacle Clinical Research
Austin, Texas
South Texas Clinical Research
Corpus Christi, Texas
Showing 40 of 169 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.